Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01318733 · ClinicalTrials.gov registry record · Phase 3
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A Phase 3 study of Rosacea, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 449
- Enrollment target
- 20
- Study locations
NCT01318733: Completed Phase 3 study of Rosacea, sponsored by Galderma R&D.
NCT01318733 is a Phase 3 study of Rosacea that has completed, run by Galderma R&D. The registered enrollment target is 449 participants, above the 224-participant average among 23 other Rosacea trials with a reported enrollment target (100% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01318733, a Phase 3 study of Rosacea, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 449 participants
- Enrollment target
- 20
- Study locations
Study Summary
A long-term, open-label, non-comparative safety and efficacy study of CD07805/47 gel 0.5% once daily in subjects with moderate to severe facial erythema associated with rosacea.
Primary Outcome
Static evaluation of erythema severity using the Clinician Erythema Assessment (CEA) - Grade/Description 0 / Clear Skin with no signs of erythema 1. / Almost clear; slight redness 2. / Mild erythema; definite redness 3. / Moderate erythema; marked redness 4. / Severe erythema; fiery redness Change in CEA from Baseline CEA (T0 at Baseline visit Day 1) at T3 of each post-baseline visit, including Day 1.
Conditions Studied
Interventions
- DRUG CD07805/47 gel 0.5%
Study Locations (20)
North Carolina
- Metrolina Medical Research - Charlotte
- Dermatology, Laser & Vein Specialists of the Carolinas - Charlotte
- Wilmington Medical Research - Wilmington
- Piedmont Medical Research - Winston-Salem
Tennessee
- Rivergate Dermatology Clinical Research Center, PLLC - Goodlettsville
- East Tennessee Medical Research - Johnson City
- TriCities Medical Research - Kingsport
Colorado
- Cherry Creek Research, Inc - Denver
- Longmont Clinical PC - Longmont
Michigan
- Hamzavi Dermatology - Fort Gratiot
- Dermcenter PC- Somerset Skin Centre - Troy
California
- The Laser Institute for Dermatology - Santa Monica
Georgia
- Gwinnett Clinical Research Center, Inc - Snellville
Indiana
- Deaconess Clinic - Evansville
Kansas
- Compliant Clinical Research - Olathe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 449 participants |
| Start Date | 2011-03 |
| Est. Completion | 2012-07 |
| Phase | Phase 3 |
What the finished NCT01318733 record still lists
NCT01318733 is an interventional study that assigns participants to a tested intervention. The registered 449 participants enrollment target is mid-sized for trials with a published cap, above the 224-participant average among 23 other Rosacea trials with a reported enrollment target (100% higher).
The record links to 1 condition, with Rosacea appearing as the primary indexed condition, and to 1 intervention - of which CD07805/47 gel 0.5% is the first listed.
NCT01318733 names 20 study sites across 13 states, led by North Carolina, Tennessee, Colorado.
Frequently Asked Questions
What is clinical trial NCT01318733 about?
NCT01318733 is a clinical study titled "Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea". A long-term, open-label, non-comparative safety and efficacy study of CD07805/47 gel 0.5% once daily in subjects with moderate to severe facial erythema associated with rosacea.
What is the current status of trial NCT01318733?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 449 participants. The study started on 2011-03. Estimated completion is 2012-07.
What conditions does trial NCT01318733 study?
This clinical trial studies the following conditions: Rosacea.
What interventions are being tested in trial NCT01318733?
The interventions under investigation include: CD07805/47 gel 0.5% (DRUG).
Who is sponsoring clinical trial NCT01318733?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01318733 being conducted?
This trial has 20 study locations across California, Colorado, Georgia, Indiana, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01318733's enrollment target sits among peer trials
449 4th of 23 higher than 20 of 23 other Rosacea trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rosacea trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea
COMPLETED · Phase 3
-
Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
COMPLETED · Phase 3
-
Bioequivalence Study of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea on the Face
COMPLETED · Phase 3
-
Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel
COMPLETED · Phase 3
-
Effects of Oral Supplement Containing L-Histidine and Antioxidants on the Skin Barrier Function and Systemic Inflammation in Rosacea
RECRUITING · NA
-
Evaluating Use of Topical Imipramine and Amitriptyline in Reducing Ultraviolet B Light-Induced Redness in Patients With Rosacea
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00515060 · 450 participants
Psychophysical Studies of Cancer Therapy Pain
- NCT01257269 · 450 participants
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
- NCT03047161 · 450 participants
Electrophysiology of Fetal Arrhythmia
- NCT03269630 · 450 participants
New Orleans Pulmonary Hypertension Biobank
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia